Randomised, double-masked trial to compare the efficacy, safety and immunogenicity of the biosimilar aflibercept FYB203 with reference aflibercept in patients with neovascular age-related macular degeneration

Authors

Institutions

Publication Details

Journal
BMJ Open Ophthalmology
Published
2026-01-01
DOI
https://doi.org/10.1136/bmjophth-2025-002398
Primary Topic
Biosimilars and Bioanalytical Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Randomised, double-masked trial to compare the efficacy, safety and immunogenicity of the biosimilar aflibercept FYB203 with reference aflibercept in patients with neovascular age-related macular degeneration

Alexis Rozenknop, Sigrid Balser, Björn Capsius, Theodor Tiko et al.
BMJ Open Ophthalmology
Biosimilars and Bioanalytical Methods
article

Randomised, double-masked trial to compare the efficacy, safety and immunogenicity of the biosimilar aflibercept FYB203 with reference aflibercept in patients with neovascular age-related macular degeneration

Alexis Rozenknop, Sigrid Balser, Björn Capsius, Theodor Tiko, R Hole, Nicole Preissinger, András Papp
article en

Abstract

No abstract available for this paper.
BMJ Open OphthalmologyVol. 11(1)
Semmelweis University (HU), MorphoSys (Germany) (DE)
Good health and well-being
Openalex Percentile: Top 96%
Biosimilars and Bioanalytical Methods
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.